Gland Pharma bags USFDA nod for Cangrelor for Injection

Written by Medical Dialogues Bureau Published On 2021-12-11T16:23:10+05:30 | Updated On 11 Dec 2021 4:23 PM IST

Gland Pharma bags USFDA nod for Cangrelor for Injection

Hyderabad: Gland Pharma Limited has recently received a tentative approval from the United States Food and Drug Administration (US FDA) for Cangrelor for Injection, 50 mg/vial Single-Dose Vials.

"Gland Pharma believes that we are amongst one of the first to files for this product and may be eligible for 180 days of generic drug exclusivity," the company said in a release.

Gland Pharma will launch the product with its marketing partner on receipt of final approval.

Read also: Gland Pharma eyeing complex injectables, biosimilar space to fuel future growth

Gland Pharma, a generic injectable focused pharmaceutical company was established in 1978 in Hyderabad.

It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology and ophthalmic solutions a

Read also: Gland Pharma gets tentative USFDA nod for generic version of Bridion injection

Gland Pharmagland pharma newsusfdacangrelor

Medical Dialogues Bureau

Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.